Consequently, CNQX can inhibit the intestinal inflammatory response in mice with colitis, inhibit the mucosal barrier injury, increase the expression of tight junction proteins (including occludin and claudin‐1) and decrease the expression levels of MyD88, TLR4 and MD2. The gene discussed is TLR4; the disease is colitis.